This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

BG Medicine Welcomes Inclusion Of Galectin-3 In 2014 Indian Consensus Document On Cardiac Biomarkers

Stock quotes in this article: BGMD

WALTHAM, Mass., March 10, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that galectin-3 testing has been recognized for the first time in the newly issued 2014 Indian Consensus Document on Cardiac Biomarkers published by the Cardiological Society of India. [1] The Consensus Document on Cardiac Biomarkers reviews cardiac blood tests that are available for diagnosis and management in heart failure, and provides recommendations for physicians on their use and utility in caring for heart failure patients.

In the 2014 Indian Consensus Document on Cardiac Biomarkers, galectin-3 testing has been included, in addition to testing for the natriuretic peptides, B-type natriuretic peptide (BNP) and NT-proBNP, for use in heart failure. The consensus document states: "B-type natriuretic peptide, in conjunction with Galectin-3, may be used to identify those patients at higher risk of readmission or death thus allowing the physician to better match the level of care to an individual patient's needs. These biomarkers are helpful to physicians, emergency physicians, and cardiologists in day-to-day practice."

Heart failure in India has been conservatively estimated to affect up to 4.6 million people, with up to 1.8 million new diagnoses made each year. [2]

"In India, heart failure is becoming a common reason for hospitalization in patients with cardiovascular disease," commented Jamshed J. Dalal, M.D., D.M., Ph.D., Director of Cardiology at Kokilaben Hospital in Mumbai. "Rapid and accurate diagnosis with a technique that is easily available, cost effective and rapidly performed with both high sensitivity and specificity is of immense value to both the physician and the patient. Cardiac biomarkers fit the bill in all aspects, and rightfully are gaining popularity. However, they still need to be used more frequently and more appropriately. Galectin-3, a relatively new cardiac biomarker, further enhances the unique value that this testing provides. Prediction of future events and optimization of treatment with these tests is an added benefit that should be fully utilized by all clinicians treating patients with heart failure."

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs